Clinical Trial Update: Extension Study on the Efficacy and Safety of Enteric-coated Mycophenolate Sodium Administered in de Novo Kidney Transplant Patients [Phase 4]

View source ↗

Summary

Extension Phase 4 study assessing the efficacy and safety of enteric-coated mycophenolate sodium in de novo kidney transplant recipients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• MYFORTIC (MYCOPHENOLIC ACID)

Snippet

Sponsor: Novartis | Conditions: De Novo Kidney Transplantation | Phase 4 | Status: COMPLETED